Pierre Fabre Laboratories Expands Innovative Treatment Portfolio
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors recognized for their best-in-class potential, specifically aimed at treating non-small cell lung cancer (NSCLC), a prevalent and serious form of lung cancer.
Acquisition of Worldwide Rights
Pierre Fabre Laboratories is excited to announce the acquisition of worldwide rights for PFL-721 and PFL-241 from Antares Therapeutics, Inc. This strategic move allows Pierre Fabre to broaden its existing agreement with Scorpion Therapeutics, taking leading responsibility for the clinical development of these innovative treatments.
About PFL-721 and PFL-241
PFL-721 serves as a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor. This therapy is on the brink of transitioning into dose optimization within its pioneering clinical trials targeting NSCLC. Meanwhile, PFL-241 is designed to be a mutant-specific, brain-penetrant, fourth-generation EGFR inhibitor. It is currently in the dose escalation phase of its first-in-human trial, aiming to tackle C797S resistance mutations commonly found in NSCLC patients.
The Challenge of NSCLC
NSCLC represents the most prevalent subtype of lung cancer, with various EGFR mutations identified as the most frequent drivers, appearing in approximately 14-38 percent of tumors globally. This high incidence underscores the urgent need for effective treatment solutions.
Pierre Fabre's Commitment to R&D
With this acquisition, Pierre Fabre Laboratories fully secures the global rights for all assets within their R&D portfolio, including exarafenib, PFL-002 (formerly VERT-002), PFL-721, and PFL-241. Francesco Hofmann, the Head of Research and Development for Medical Care at Pierre Fabre Laboratories, stated, "With this agreement with Antares, we are committed to advancing clinical development, focusing on delivering innovative precision medicines to patients with serious unmet medical needs."
About Pierre Fabre Laboratories
Pierre Fabre Laboratories ranks as the second-largest dermo-cosmetics company globally and stands out as one of Europe's leading pharmaceutical laboratories. Their portfolio in Dermo-cosmetics & Personal Care features notable international brands like Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. Their Medical Care division encompasses five primary therapeutic areas: oncology, dermatology, rare diseases, primary care, and family health care.
Frequently Asked Questions
What are PFL-721 and PFL-241?
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors developed for treating non-small cell lung cancer (NSCLC).
Who acquired the rights to these drugs?
Pierre Fabre Laboratories acquired the worldwide rights from Antares Therapeutics, Inc.
What is the significance of these drugs?
These drugs are designed to target specific mutations in NSCLC, addressing a significant medical need for effective treatments.
What is the next step for PFL-721 and PFL-241?
PFL-721 will enter dose optimization in clinical trials, while PFL-241 is currently in the dose escalation phase.
What does the acquisition mean for Pierre Fabre Laboratories?
This acquisition allows Pierre Fabre to enhance its R&D portfolio and reinforce its commitment to developing innovative solutions for patients with significant medical needs.
